An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer

NCT07667751 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Ovary Cancer

Interventions

DRUG: Sunitinib、Olaparib、Tolilizumab

Sponsor

Bai-Rong Xia

Collaborators

[object Object]